Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14758622 | 1.00 | KMO (0.56) | KMOTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL16217844 | 0.94 | KMO (0.58) | KMOTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL14742516 | 0.79 | KMO (0.57) | KMOCNR1CNR2 | |
| SCHEMBL29563786 | 0.75 | HTT (0.65) | TAS1R3TAS1R1TAS1R2ALDH1A1TSHR | |
| SCHEMBL30429275 | 0.74 | KMO (0.58) | KMOCNR2 | |
| SCHEMBL16217834 | 0.74 | KMO (0.58) | KMOCNR2 | |
| SCHEMBL30428213 | 0.73 | KMO (0.55) | KMO | |
| SCHEMBL14758623 | 0.73 | KMO (0.55) | KMO | |
| SCHEMBL16794033 | 0.73 | ALDH1A1 (0.43) | KMOTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL3101304 | 0.73 | ALDH1A1 (0.67) | TAS1R3TAS1R1TAS1R2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428464-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428464-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, HAAO | KMO 1/4885TAS1R3 4744/4885TAS1R1 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.